Propel Bio Management, LLC
CIK 0001969764 · LOS ANGELES, CA · Quarter end: 2026-06-30 · Filed on: 2026-08-13 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$191.1M
2026 Q2
Positions
29
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
68.1%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
PAGP
PLAINS GP HOLDINGS LP-CL
16.2%
ACHV
ACHIEVE LIFE SCIENCES INC
13.8%
CORT
CORCEPT THERAPEUTICS INC
6.2%
PHAT
PHATHOM PHARMACEUTICALS I
6.0%
DCTH
DELCATH SYSTEMS INC
5.7%
MIST
MILESTONE PHARMACEUTICALS
5.2%
CMPS
COMPASS PATHWAYS PLC
4.2%
KYTX
KYVERNA THERAPEUTICS INC
4.1%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.